Marschang; Diane L. - US Patent Attorneys and Agents

Attorney: Marschang; Diane L.

Number of patents: 38
Last date: February 28, 2012

Browse patents
Browse applications

Number	Title	Issue Date
8124339	Assays and methods using biomarkers Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue...	02/28/2012
7855066	Methods for making Apo-2 ligand using divalent metal ions Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided...	12/21/2010
7842668	Apo-2 ligand/trail formulations The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as...	11/30/2010
7741282	ApO2 ligand/TRAIL formulations The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as...	06/22/2010
7629136	Assays and methods using biomarkers Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue...	12/08/2009
7592439	Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L...	09/22/2009
7314619	Inducing apoptosis using anti-Apo-2 antibodies Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. ...	01/01/2008
7252994	Human DR4 antibodies and uses thereof Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided. ...	08/07/2007
7198913	Nucleic acids encoding a tumor necrosis factor homolog The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid s...	04/03/2007
7101850	WISP polypeptides and nucleic acids encoding same Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide mol...	09/05/2006
6998116	Apo-2 ligand A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to...	02/14/2006
6764679	Antibodies to DcR3 Polypeptide, a TNFR Homolog A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided. ...	07/20/2004
6746668	Apo-2 ligand A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to...	06/08/2004
6740739	Substitutional variants of APO-2 ligand A novel cytokine, designated Apo-2 ligand, which induces mammalian cancer cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibo...	05/25/2004
6686455	Tumor necrosis factor A cytotoxic protein designated tumor necrosis factor is identified in nature. It is recovered in substantially homogeneous form by treatment with hydrophobic substances and ion exchange resins. The protein is conclusively identified by its amino acid sequ...	02/03/2004
6586206	Methods for making recombinant proteins using apoptosis inhibitors The invention provided improved methods of making and producing recombinant proteins in in vitro cultures of host cells using apoptosis inhibitors. The use of one or more apoptosis inhibitors in the methods can reduce apoptosis in the cell cultures and ma...	07/01/2003
6551585	Use of tumor necrosis factor as an adjuvant Tumor necrosis factors, alone or together with cytokines such as IL-1 or IFN-γ, are capable of serving as non-toxic vaccine adjuvants....	04/22/2003
6534061	Tumor necrosis factor receptor homologs and nucleic acids encoding the same The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nuc...	03/18/2003
6500922	Tumor necrosis factor receptor-associated factors The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF ...	12/31/2002
6469144	Apo-2LI and Apo-3 polypeptides Novel polypeptides, designated Apo-3 and Apo-2LI, involved in apoptosis are provided. Compositions including chimeric molecules, nucleic acids, and antibodies are also provided....	10/22/2002
6462176	Apo-3 polypeptide Novel polypeptides, designated Apo-3, which are capable of stimulating or inducing apoptosis are provided. Compositions including Apo-3 chimeras, nucleic acid encoding Apo-3, and antibodies to Apo-3 are also provided....	10/08/2002
6448225	Human growth hormone aqueous formulation A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated methods for preparing, s...	09/10/2002
6387657	WISP polypeptides and nucleic acids encoding same Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric poly...	05/14/2002
6342369	Apo-2-receptor Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided....	01/29/2002
6177543	Recombinant lymphotoxin Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing un...	01/23/2001
6046048	Apo-2 ligand A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and an...	04/04/2000
6030945	Apo-2 ligand A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and an...	02/29/2000
5879910	Hepatocyte growth factor protease domain variants The invention concerns hepatocyte growth factor (HGF) variants that compise an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF....	03/09/1999
5855918	Cystic fibrosis therapy The invention provides methods for treating cystic fibrosis and other pathological conditions in mammals using hepatocyte growth factor ("HGF"). The invention also provides articles of manufacture and kits containing HGF....	01/05/1999
5824509	Recombinant lymphotoxin cDNA and variants Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing un...	10/20/1998
5795967	Tumor necrosis factor antagonists and their use Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing a...	08/18/1998
5763394	Human growth hormone aqueous formulation A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for pr...	06/09/1998
5747023	Cancer therapy using lymphotoxin Methods and compositions are provided which include use of lymphotoxin (LT) and one or more other anti-cancer therapies for treating cancer in vivo or ex vivo. LT can be employed, for instance, with chemotherapy or radiation therapy to provide improved an...	05/05/1998
5686292	Hepatocyte growth factor receptor antagonist antibodies and uses thereof Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially in...	11/11/1997
5683688	Unglycosylated recombinant human lymphotoxin polypeptides and compositions Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing un...	11/04/1997
5672347	Tumor necrosis factor antagonists and their use Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing a...	09/30/1997
5646036	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially in...	07/08/1997
5580963	Single-chain hepatocyte growth factor variants The invention concerns hepatocyte growth factor (HGF) variants that are resistant to proteolytic cleavage by enzymes capable of in vivo conversion of HGF into its two-chain form. The single-chain HGF variants, which preferably have an amino acid alteratio...	12/03/1996

PatentStorm

Did You Know...

PatentStorm News

Attorney: Marschang; Diane L.